Honors & Awards
Faculty of Health Sciences Graduate Programs Outstanding Thesis Award, McMaster University (2017)
Faculty of Health Sciences Graduate Programs Excellence Award, McMaster University (2016)
McMaster Graduate Studies International Excellence Award, McMaster University (2014-2015)
Outstanding Oral Presentation Award, Faculty of Health Sciences, McMaster University (2014)
Chemical Biology Travel Award, McMaster University (2012-2013)
McMaster Graduate Studies International Excellence Award, McMaster University (2012-2013)
Doctor of Philosophy, McMaster University (2016)
Bachelor of Science, King Saud University (2009)
Aimen Zlitni, John F. Valliant. "CanadaTargeted Molecular Imaging Contrast Agents.", Aug 1, 2015
Development of prostate specific membrane antigen targeted ultrasound microbubbles using bioorthogonal chemistry.
2017; 12 (5): e0176958
Prostate specific membrane antigen (PSMA) targeted microbubbles (MBs) were developed using bioorthogonal chemistry. Streptavidin-labeled MBs were treated with a biotinylated tetrazine (MBTz) and targeted to PSMA expressing cells using trans-cyclooctene (TCO)-functionalized anti-PSMA antibodies (TCO-anti-PSMA). The extent of MB binding to PSMA positive cells for two different targeting strategies was determined using an in vitro flow chamber. The initial approach involved pretargeting, where TCO-anti-PSMA was first incubated with PSMA expressing cells and followed by MBTz, which subsequently showed a 2.8 fold increase in the number of bound MBs compared to experiments performed in the absence of TCO-anti-PSMA. Using direct targeting, where TCO-anti-PSMA was linked to MBTz prior to initiation of the assay, a 5-fold increase in binding compared to controls was observed. The direct targeting approach was subsequently evaluated in vivo using a human xenograft tumor model and two different PSMA-targeting antibodies. The US signal enhancements observed were 1.6- and 5.9-fold greater than that for non-targeted MBs. The lead construct was also evaluated in a head-to-head study using mice bearing both PSMA positive or negative tumors in separate limbs. The human PSMA expressing tumors exhibited a 2-fold higher US signal compared to those tumors deficient in human PSMA. The results demonstrate both the feasibility of preparing PSMA-targeted MBs and the benefits of using bioorthogonal chemistry to create targeted US probes.
View details for DOI 10.1371/journal.pone.0176958
View details for PubMedID 28472168
In vivo Biodistribution of Radiolabeled Acoustic Protein Nanostructures.
Molecular imaging and biology : MIB : the official publication of the Academy of Molecular Imaging
Contrast-enhanced ultrasound plays an expanding role in oncology, but its applicability to molecular imaging is hindered by a lack of nanoscale contrast agents that can reach targets outside the vasculature. Gas vesicles (GVs)-a unique class of gas-filled protein nanostructures-have recently been introduced as a promising new class of ultrasound contrast agents that can potentially access the extravascular space and be modified for molecular targeting. The purpose of the present study is to determine the quantitative biodistribution of GVs, which is critical for their development as imaging agents.We use a novel bioorthogonal radiolabeling strategy to prepare technetium-99m-radiolabeled ([(99m)Tc])GVs in high radiochemical purity. We use single photon emission computed tomography (SPECT) and tissue counting to quantitatively assess GV biodistribution in mice.Twenty minutes following administration to mice, the SPECT biodistribution shows that 84 % of [(99m)Tc]GVs are taken up by the reticuloendothelial system (RES) and 13 % are found in the gall bladder and duodenum. Quantitative tissue counting shows that the uptake (mean ± SEM % of injected dose/organ) is 0.6 ± 0.2 for the gall bladder, 46.2 ± 3.1 for the liver, 1.91 ± 0.16 for the lungs, and 1.3 ± 0.3 for the spleen. Fluorescence imaging confirmed the presence of GVs in RES.These results provide essential information for the development of GVs as targeted nanoscale imaging agents for ultrasound.
View details for DOI 10.1007/s11307-017-1122-6
View details for PubMedID 28956265
- Catching Bubbles: Targeting Ultrasound Microbubbles Using Bioorthogonal Inverse-Electron-Demand Diels-Alder Reactions ANGEWANDTE CHEMIE-INTERNATIONAL EDITION 2014; 53 (25): 6459-6463
I-125-Tetrazines and Inverse-Electron-Demand Diels-Alder Chemistry: A Convenient Radioiodination Strategy for Biomolecule Labeling, Screening, and Biodistribution Studies
2016; 27 (1): 207-216
A convenient method to prepare radioiodinated tetrazines was developed, such that a bioorthogonal inverse electron demand Diels-Alder reaction can be used to label biomolecules with iodine-125 for in vitro screening and in vivo biodistribution studies. The tetrazine was prepared by employing a high-yielding oxidative halo destannylation reaction that concomitantly oxidized the dihydrotetrazine precursor. The product reacts quickly and efficiently with trans-cyclooctene derivatives. Utility was demonstrated through antibody and hormone labeling experiments and by evaluating products using standard analytical methods, in vitro assays, and quantitative biodistribution studies where the latter was performed in direct comparison to Bolton-Hunter and direct iodination methods. The approach described provides a convenient and advantageous alternative to conventional protein iodination methods that can expedite preclinical development and evaluation of biotherapeutics.
View details for DOI 10.1021/acs.bioconjchem.5b00609
View details for Web of Science ID 000368651600023
View details for PubMedID 26699913
- Synthesis, characterization and radiolabeling of carborane-functionalized tetrazines for use in inverse electron demand Diels-Alder ligation reactions JOURNAL OF ORGANOMETALLIC CHEMISTRY 2015; 791: 204-213
The synthesis, magnetic purification and evaluation of Tc-99m-labeled microbubbles
NUCLEAR MEDICINE AND BIOLOGY
2011; 38 (8): 1111-1118
Ultrasound (US) contrast agents based on microbubbles (MBs) are being investigated as platforms for drug and gene delivery. A methodology for determining the distribution and fate of modified MBs quantitatively in vivo can be achieved by tagging MBs directly with (99m)Tc. This creates the opportunity to employ dual-modality imaging using both US and small animal SPECT along with quantitative ex vivo tissue counting to evaluate novel MB constructs.A (99m)Tc-labeled biotin derivative ((99m)TcL1) was prepared and incubated with streptavidin-coated MBs. The (99m)Tc-labeled bubbles were isolated using a streptavidin-coated magnetic-bead purification strategy that did not disrupt the MBs. A small animal scintigraphic/CT imaging study as well as a quantitative biodistribution study was completed using (99m)TcL1 and (99m)Tc-labeled bubbles in healthy C57Bl-6 mice.The imaging and biodistribution data showed rapid accumulation and retention of (99m)Tc-MBs in the liver (68.2±6.6 %ID/g at 4 min; 93.3±3.2 %ID/g at 60 min) and spleen (214.2±19.7 %ID/g at 4 min; 213.4±19.7 %ID/g at 60 min). In contrast, (99m)TcL1 accumulated in multiple organs including the small intestine (22.5±3.6 %ID/g at 4 min; 83.4±5.9 %ID/g at 60 min) and bladder (184.0±88.1 %ID/g at 4 min; 24.2±17.7 %ID/g at 60 min).A convenient means to radiolabel and purify MBs was developed and the distribution of the labeled products determined. The result is a platform which can be used to assess the pharmacokinetics and fate of novel MB constructs both regionally using US and throughout the entire subject in a quantitative manner by employing small animal SPECT and tissue counting.
View details for DOI 10.1016/j.nucmedbio.2011.04.008
View details for Web of Science ID 000298070400005
View details for PubMedID 21741260